DelveInsight’s, “Chronic Heart Failure Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Chronic Heart Failure pipeline landscape. It covers the Chronic Heart Failure pipeline drug profiles, including Chronic Heart Failure clinical trials and nonclinical stage products. It also covers the Chronic Heart Failure therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Chronic Heart Failure Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Chronic Heart Failure Pipeline landscape @ Chronic Heart Failure Pipeline Outlook
Chronic Heart Failure Overview
Chronic heart failure (CHF) is a major public health problem in industrialized societies with an incidence approaching 10 per 1,000 population after age 65 and an age-dependent prevalence of less than 1% between ages 45-55, 2-5% between ages 65-75, and approximately 10% for patients aged 80 years or more. HF is a complex clinical syndrome characterized by the inability of the heart to provide the cardiac output needed by the organism at normal end-diastolic ventricular pressures.
Recent Developmental Activities in the Chronic Heart Failure Treatment Landscape
For further information, refer to the detailed Chronic Heart Failure Drugs Launch, Chronic Heart Failure Developmental Activities, and Chronic Heart Failure News, click here for Chronic Heart Failure Ongoing Clinical Trial Analysis
Chronic Heart Failure Emerging Drugs Profile
Neucardin is a. Recombinant human neuregulin-1 (Neucardin), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart contraction and relaxation, thereby improving cardiac function and reversing pathological ventricular remodeling, and significantly reducing death rate and readmission rate while improving the quality of life.
Omecamtiv mecarbil is an investigational, selective, small molecule cardiac myosin activator, the first of a novel class of myotropes1 designed to directly target the contractile mechanisms of the heart, binding to and recruiting more cardiac myosin heads to interact with actin during systole. Omecamtiv mecarbil is designed to increase the number of active actin-myosin cross bridges during each cardiac cycle and consequently augment the impaired contractility that is associated with heart failure with reduced ejection fraction (HFrEF). Preclinical research has shown that omecamtiv mecarbil increases cardiac contractility without increasing intracellular myocyte calcium concentrations or myocardial oxygen consumption.
Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Heart Failure.
Chronic Heart Failure Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Chronic Heart Failure. The companies which have their Chronic Heart Failure drug candidates in the most advanced stage, i.e. Pre-Registration include, Zensun (Shanghai) Sci & Tech.
Find out more about the Chronic Heart Failure Pipeline Segmentation, Therapeutics Assessment, and Chronic Heart Failure Emerging Drugs @ Chronic Heart Failure Treatment Landscape
Scope of the Chronic Heart Failure Pipeline Report
Dive deep into rich insights for drugs for Chronic Heart Failure Pipeline Companies and Therapies, click here @ Chronic Heart Failure Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Chronic Heart Failure Mergers and acquisitions, Chronic Heart Failure Licensing Activities @ Chronic Heart Failure Recent Trends, and Future Perspectives
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/